The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Open accessAbstract
BACKGROUND: This study compared bortezomib with high-dose dexamethasone in patients with relapsed multiple myeloma who had received one to three previous therapies. METHODS: We randomly assigned 669 patients with relapsed myeloma to receive either an intravenous bolus of bortezomib (1.3 mg per square meter of body-surface area) on days 1, 4, 8, and 11 for eight three-week cycles, followed by treatment on days 1, 8, 15, and 22 for three five-week cycles, or high-dose dexamethasone (40 mg orally) on days 1 through 4, 9 through 12, and 17 through 20 for four five-week cycles, followed by treatment on days 1 through 4 for five four-week cycles. Patients who were assigned to receive dexamethasone were permitted to cross over to receive bortezomib in a companion study after disease progression. RESULTS: Patients treated with bortezomib had higher response rates, a longer time to progression (the primary end point), and a longer survival than patients treated with dexamethasone. The combined complete and partial response rates were 38 percent for bortezomib and 18 percent for dexamethasone (P<0.001), and the complete response rates were 6 percent and less than 1 percent, respectively (P<0.001). Median times to progression in the bortezomib and dexamethasone groups were 6.22 months (189 days) and 3.49 months (106 days), respectively (hazard ratio, 0.55; P<0.001). The one-year survival rate was 80 percent among patients taking bortezomib and 66 percent among patients taking dexamethasone (P=0.003), and the hazard ratio for overall survival with bortezomib was 0.57 (P=0.001). Grade 3 or 4 adverse events were reported in 75 percent of patients treated with bortezomib and in 60 percent of those treated with dexamethasone. CONCLUSIONS: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAttal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Self-citationHideshima, T., Richardson, P. G. G., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., & Anderson, K. C. (2001) · PubMed · Cited by 1,508
Self-citationMolecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 741
Self-citationA phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., et al. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05188.x · Cited by 740
Self-citationThalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.139 · Cited by 566
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., et al. (2003) · Blood · doi:10.1182/blood-2002-08-2543 · Cited by 566
Self-citationBarlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., et al. (2001) · Blood · doi:10.1182/blood.v98.2.492 · Cited by 541
LeBlanc, R., Catley, L. P., Hideshima, T., Lentzsch, S., Mitsiades, C. S., Mitsiades, N., Neuberg, D. S., Goloubeva, O. G., Pien, C. S., Adams, J., et al. (2002) · PubMed · Cited by 450
Self-citationPrimary dexamethasone treatment of multiple myeloma
Alexanian, R., Dimopoulos, M., Delasalle, K., & Barlogie, B. (1992) · Blood · doi:10.1182/blood.v80.4.887.887 · Cited by 366
Clinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
High-Dose Glucocorticoid Treatment of Resistant Myeloma
ALEXANIAN, R., BARLOGIE, B., & DIXON, D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-8 · Cited by 248
Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M., & Malm, C. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01983.x · Cited by 242
Hermine, O., Dombret, H., Poupon, J., Arnulf, B., Lefrère, F., Rousselot, P. H., Damaj, G. L., Delarue, R., Fermand, J. P., Brouet, J. C., et al. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200374 · Cited by 128
Management of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi, P., Zamagni, E., Cellini, C., Ronconi, S., Patriarca, F. F., Ballerini, F., Musto, P., Raimondo, F. D., Ledda, A., Lauria, F., et al. (2002) · PubMed · Cited by 111
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Neben, K., Moehler, T. M., Benner, A., Kraemer, A., Egerer, G., Ho, A. D., & Goldschmidt, H. (2002) · PubMed · Cited by 105
Self-citationSonneveld, P., Suciu, S., Weijermans, P., Beksaç, M., Neuwirtová, R., Solbu, G., Lokhorst, H. M., der Lelie, J. V., Döhner, H., Gerhartz, H., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03171.x · Cited by 93
Self-citationThalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus, M., Dmoszyńska, A., Soroka‐Wojtaszko, M., Jawniak, D., Legiec, W. M., Ciepnuch, H., Hellmann, A. R., Wolska-Smoleń, T., Skotnicki, A. B., & Mańko, J. (2001) · PubMed · Cited by 85
Yakoub‐Agha, I., Attal, M., Dumontet, C., Delannoy, V., Moreau, P., Berthou, C., Lamy, T., Grosbois, B., Dauriac, C., Dorvaux, V., et al. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200175 · Cited by 84
Self-citationThalidomide with or without dexamethasone for refractory or relapsing multiple myeloma
Alexanian, R., Weber, D., Anagnostopoulos, A., Delasalle, K. B., Wang, M. L., & Rankin, K. (2003) · Seminars in Hematology · doi:10.1053/j.seminhematol.2003.09.006 · Cited by 52
Kalish, L. A., Kyle, R. A., Hahn, R. G., Tormey, D. C., Oken, M. M., & Gertz, M. A. (1995) · American Journal of Clinical Oncology · doi:10.1097/00000421-199512000-00003 · Cited by 41
Gene therapy for inherited disorders of haematopoietic cells
Klein, C., & Baum, C. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200366 · Cited by 23
Mineur, Menard, Loët, X. L., Bernard, Grosbois, Pollet, Azais, Laporte, Doyen, Gramont, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00997.x · Cited by 18
Therapy of Primary Resistant and Relapsed Multiple Myeloma
Barlogie, B., & Alexanian, R. (2009) · Onkologie · doi:10.1159/000216008 · Cited by 11
Research works printed but not linked: 15
- 10.1002/ajh.2830360303 · doi:10.1002/ajh.2830360303
- Hideshima T, 2001, Cancer Res, 61, 3071
- LeBlanc R, 2002, Cancer Res, 62, 4996
- Calhoun EA, 2000, Proc Am Soc Clin Oncol, 19, 446a
- Durie BGM, 1999, Blood, 94, 316
- Grosbois B, 2001, Blood, 98, 689
- Hus M, 2001, Haematologica, 86, 404
- Rajkumar SV, 2000, Blood, 96, 168a
- Raza SN, 2000, Blood, 96, 168a
- Tosi P, 2002, Haematologica, 87, 408
- Neben K, 2002, Clin Cancer Res, 8, 3377
- 10.1111/j.1365-2141.1992.tb06466.x · doi:10.1111/j.1365-2141.1992.tb06466.x
- Niesvizky R, 2003, Proc Am Soc Clin Oncol, 22, 582
- Rajkumar SV, 2004, J Clin Oncol, 22, 560s, 10.1200/jco.2004.22.14_suppl.6508 · doi:10.1200/jco.2004.22.14_suppl.6508
- Richardson PG, 2003, Blood, 102, 149a
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citation
Metadata
- Authors
- Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J. F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W. S., Boral, A. L., Esseltine, D. L., Porter, J. B., Schenkein, D., & Anderson, K. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-06-16
- Volume
- 352
- Issue
- 24
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2124560610
- Cited by
- 2,491
- References
- 31
- FWCI
- 100.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.